BVF Inc. IL lessened its holdings in Tocagen Inc (NASDAQ:TOCA) by 47.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 556,683 shares of the company’s stock after selling 506,345 shares during the period. BVF Inc. IL’s holdings in Tocagen were worth $5,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in Tocagen by 52.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock valued at $7,886,000 after purchasing an additional 218,100 shares during the period. Goldman Sachs Group Inc. bought a new position in Tocagen in the 2nd quarter valued at $366,000. Artal Group S.A. bought a new position in Tocagen in the 4th quarter valued at $1,025,000. Blankinship & Foster LLC bought a new position in Tocagen in the 4th quarter valued at $412,000. Finally, Pure Financial Advisors Inc. bought a new position in Tocagen in the 4th quarter valued at $1,324,000. Hedge funds and other institutional investors own 32.96% of the company’s stock.
Tocagen Inc (NASDAQ:TOCA) opened at $12.91 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03. The firm has a market capitalization of $259.56 and a price-to-earnings ratio of -6.46. Tocagen Inc has a 12 month low of $8.60 and a 12 month high of $17.95.
TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3254741/tocagen-inc-toca-holdings-cut-by-bvf-inc-il.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.